CLL
Conference Coverage
Some mutation testing can be useful at CLL diagnosis
CHICAGO –
Conference Coverage
Novel options for treating hairy cell leukemia
NEW YORK –
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
News
FDA approves new drug for CLL/SLL and follicular lymphoma
Duvelisib (Copiktra) has full approval to treat CLL/SLL and accelerated approval to treat FL.
News
FDA approves new hairy cell leukemia drug
Moxetumomab pasudotox-tdfk (Lumoxiti) is approved to treat adults with relapsed or refractory hairy cell leukemia.
News from the FDA/CDC
Venetoclax label now includes MRD data
The MURANO trial showed high rates of minimal residual disease negativity in patients treated with the venetoclax combination.
From the Journals
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
Adverse events were largely seen during the first year of treatment and decreased over time.
From the Journals
Combo treatment yields MRD-negative remissions in CLL
Researchers with the German CLL Study Group said the combination of obinutuzumab plus venetoclax achieved fast responses.
From the Journals
Caution urged over real-world bleeding risk with ibrutinib
Ibrutinib was linked to an almost 20-fold increased risk of major bleeding in blood cancer patients taking concomitant antiplatelet and...
From the Journals
New chronic lymphocytic leukemia guidelines from the UK
The updated guidelines call for assessing TP53 mutations and deletions before each line of therapy.
From the Journals
Isavuconazole resolved invasive fungal disease in patients on ibrutinib
Four of eight patients experienced clinical and radiographic resolution; three improved.